# Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

Study · id `cardio:ct-nct03400800` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03400800](<https://clinicaltrials.gov/study/NCT03400800>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03400800

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1617 participants.

## Technical summary

Registry record NCT03400800. Randomized; double masking; primary purpose treatment. Start 2017-11-01 (actual); primary completion 2019-07-31 (actual). Results posted on 2020-08-21.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1617 participants (enrolled count; ClinicalTrials.gov record NCT03400800, source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)
- Started: 2017-11-01 (actual) (ClinicalTrials.gov record NCT03400800, source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)
- Primary completion: 2019-07-31 (actual) (ClinicalTrials.gov record NCT03400800, source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)
- Completion: 2019-08-27 (actual) (ClinicalTrials.gov record NCT03400800, source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)
- Results first posted: 2020-08-21 (ClinicalTrials.gov record NCT03400800, source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)
- Countries: Czechia; Germany; Hungary; Poland; South Africa; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03400800, source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03400800-2020-08-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
- Acronym: ORION-11
- Condition: ASCVD
- Condition: Risk Factor, Cardiovascular
- Condition: Elevated Cholesterol
- Intervention (Drug): Inclisiran Sodium
- Intervention (Drug): Placebo
- Lead sponsor: The Medicines Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: The Medicines Company (`cardio:org-the-medicines-company`)

## Provenance

Content hash: b6a6017a5f01ecef870eeb77d56e9bb10e567d18b73392da45909d31147133de
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
